Bajaj Healthcare informs about press release

19 Mar 2025 Evaluate
Bajaj Healthcare has informed that Bajaj Healthcare has received recommendation from Subject Expert Committee (SEC) (Neurology & Psychiatry) of Central Drugs Standard Control Organisation (CDSCO) to conduct Phase III clinical trials for Cenobamate Tablets 12.5mg, 25mg, 50mg, 100mg, 150mg & 200mg. The press release in this regard, being issued by the Company.

The above information is a part of company’s filings submitted to BSE.

Bajaj Healthcare Share Price

697.70 -10.50 (-1.48%)
28-Mar-2025 11:58 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1735.45
Dr. Reddys Lab 1144.05
Cipla 1441.70
Lupin 2026.50
Zydus Lifesciences 885.70
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Please wait your portfolio is updating...